Intensified Chemotherapy with Dexrazoxane Cardioprotection in Newly Diagnosed Non-Metastatic Osteosarcoma: A Report from the Children’s Oncology Group

BACKGROUND: Although chemotherapy has improved outcome of osteosarcoma, 30–40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardioprotectant dexrazoxane would 1) support escalation of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Pediatr Blood Cancer
Prif Awduron: Schwartz, CL, Wexler, LH, Krailo, MD, Teot, LA, Devidas, M, Steinherz, LJ, Goorin, AM, Gebhardt, MC, Healey, JH, Sato, JK, Meyers, PA, Grier, HE, Bernstein, ML, Lipshultz, SE
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4779061/
https://ncbi.nlm.nih.gov/pubmed/26398490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25753
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg